Streetbeat News

Revenues

AMD

NVDA

TSM

AMD has opened new R&D centers in Taiwan as part of a $270.5 million project to advance AI and silicon photonics technologies. The company received a significant subsidy from Taiwan, and its stock has gained over 49% in the past year due to AI market growth. AMD's data center GPU revenue is expected to grow significantly in 2024.

Portfolio Pulse from Anusuya Lahiri

August 22, 2024 | 2:15 pm

PLAY

Analysts have provided mixed ratings for Dave & Buster's Enter (NASDAQ:PLAY) over the past quarter, with a majority being bullish. The average 12-month price target has decreased by 14.05% to $63.6. Despite a negative revenue trend, the company shows strong net margin, ROE, and ROA, but faces challenges in debt management.

Portfolio Pulse from Benzinga Insights

August 22, 2024 | 2:00 pm

SPY

The USA's existing home sales for July increased by 1.3% month-over-month, matching the estimated growth rate. This is an improvement from the previous month's decline of 5.1%.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 2:00 pm

MU

Micron Technology (NASDAQ:MU) has received diverse ratings from 26 analysts over the past three months, with a majority being somewhat bullish. The average 12-month price target has increased by 13.04% to $169.65. Despite positive revenue growth, Micron faces challenges with below-average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

August 22, 2024 | 2:00 pm

SPNS

Sapiens Intl Corp (NASDAQ:SPNS) has significantly outperformed the market over the past 15 years, with an average annual return of 26.56%. A $1000 investment in SPNS 15 years ago would now be worth $33,588.79. This highlights the power of compounded returns over time.

Portfolio Pulse from Benzinga Insights

August 22, 2024 | 2:00 pm

HUBB

Hubbell (NYSE:HUBB) has significantly outperformed the market over the past 5 years, with an average annual return of 25.07%. A $1000 investment in Hubbell 5 years ago would now be worth $3,058.77, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 22, 2024 | 2:00 pm

HIMS

Analysts have provided mixed ratings for Hims & Hers Health (NYSE:HIMS) over the past three months, with a majority being bullish. The average 12-month price target has increased significantly, indicating positive sentiment. The company has shown strong financial performance with high revenue growth and profitability metrics.

Portfolio Pulse from Benzinga Insights

August 22, 2024 | 2:00 pm

SPY

The USA's existing home sales for July were reported at 3.95 million, slightly above the estimated 3.94 million and higher than the previous month's 3.90 million.

Portfolio Pulse from Benzinga Newsdesk

August 22, 2024 | 2:00 pm

AXSM

Over the past three months, 14 analysts have shared their insights on Axsome Therapeutics (NASDAQ:AXSM), with a majority expressing bullish sentiments. The average 12-month price target is $132.14, with a high of $190.00 and a low of $95.00. Axsome Therapeutics, a clinical-stage biopharmaceutical company, has shown significant revenue growth but faces challenges in profitability and financial returns.

Portfolio Pulse from Benzinga Insights

August 22, 2024 | 2:00 pm

ITA

PPA

XAR

The potential return of Donald Trump to the White House has spurred increased investments in European defense-tech startups, driven by concerns over NATO and defense budgets. This has led to a rise in military spending and partnerships with venture capital firms. U.S. defense ETFs have seen slight increases in trading.

Portfolio Pulse from Benzinga Neuro

August 22, 2024 | 1:55 pm